

WHAT IS AN EL-PFDD

HERE'S WHAT YOU NEED TO KNOW
ABOUT OUR UPCOMING SEPTEMBER
11TH MEETING WITH THE FDA



Patient-Focused Drug Development (PFDD) is a process created by FDA to ensure that the voices, experiences, and priorities of patients and caregivers are meaningfully incorporated into drug development and regulatory decision-making.

An EL-PFDD meeting is organized by the patient community with FDA staff attending in a listening capacity.



WHAT WILL THE MEETING LOOK-LIKE?

Patients and caregivers will have the chance to speak directly about the **daily impact of lipodystrophy**, the **symptoms** that matter most, and **what an ideal treatment would look like**.

The majority of the meeting will follow a town-hall style discussion led by patients, so that the broadest range of lived experiences are captured.



WHY IS THIS IMPORTANT?

- It elevates your voices directly to regulators, researchers, and drug developers.
- It ensures the realities of living with lipodystrophy are central in drug development and evaluation.
- It creates a historic opportunity for our community to influence research priorities, future clinical trials, and treatment options.



INTERESTED IN ATTENDING?



September 11th, 2026



Greater DC Area



Virtual Attendance Available

**PLEASE FILL OUT THE ATTACHED FORM TO
EXPRESS YOUR INTEREST IN ATTENDING OR
SHARE WHAT YOU THINK IS VITAL FOR THE FDA
TO KNOW**